Human vs Animal Evidence for Shilajit

The types of evidence

Why animal and cell studies are done

Preclinical studies are cheaper, faster and allow experiments that can’t ethically be done in people, such as giving very high doses or examining organs. They help researchers decide which ideas are worth testing in humans and flag potential safety concerns. For shilajit, animal work has explored many areas, and reviews summarise a wide range of effects seen in animals.^[1][2]

Why results often don’t transfer

• Species differencesRats and mice process substances differently from people.
• DosesAnimal doses, scaled by weight, are often far above human servings.
• Disease modelsAn induced condition in an animal isn’t the same as the human disease.
• Direct exposure in cellsCells in a dish meet the substance directly, unlike in the gut and bloodstream.

Where shilajit stands

See evidence ratings.

An example: cancer research

Laboratory studies have reported that shilajit can affect cancer cells, including a 2016 study in liver cancer cells.^[7] A 2026 systematic review found the evidence was preclinical, with no human clinical studies.^[8] Another laboratory study found shilajit reduced the effect of two chemotherapy drugs on lung cancer cells,^[9] a reminder that cell results can point in unexpected directions; see cancer research.

Animal studies and safety

Animal studies are particularly useful for safety. A 91-day study in rats found no significant toxicity at the doses tested.^[10] That is reassuring, but it doesn’t capture species differences, rare reactions or contamination in other products; see toxicology.

Reading claims based on animal evidence

When a product says shilajit “boosts immunity” or “regulates blood sugar”, check whether the evidence is human or preclinical. For both, it is preclinical. Phrases such as “studies show” often hide this. A claim backed only by animal or cell studies should be read as “researchers have seen this in animals”, not “this works in people”; see claims checker.

How our ratings treat preclinical evidence

On our scale, a topic supported only by animal or cell research is rated “Preclinical only”, one step above “Not studied”. It can’t reach “Limited” or higher without human trials, however many animal studies exist; see our evidence rating system.

Putting it into practice

Each time you meet a shilajit claim, ask one question first: was this studied in people? If the answer is no, treat the claim as an interesting idea. If yes, move on to how many people, which preparation and for how long; see how to read a study.

Why animal doses are hard to translate

Animal studies often give doses that, scaled by body weight, would be far larger than a human serving. Even with scaling formulas, species differ in how quickly they absorb and clear substances. A result at a high animal dose may not occur at the small amounts people actually take, and a safe animal dose doesn’t automatically translate into a safe human dose.

The evidence hierarchy

Researchers often describe evidence as a ladder: cell studies at the bottom, then animal studies, then observational human studies, then randomised controlled trials, and systematic reviews of good trials at the top. Each step up gives more confidence that a result applies to people. Shilajit has plenty of evidence on the lower rungs and only a few trials on the higher ones.

In short

Preclinical studies ask “could this work?” Human trials ask “does it work in people?” Only the second can support a benefit claim, and shilajit has relatively few of them.

Further reading

For how we weigh each kind of evidence, see our evidence rating system and evidence gaps. Both explain why so few topics rise above Preclinical only on our scale.

The bottom line

Animal and cell studies are valuable for exploring ideas and safety, but they don’t prove effects in people. Several shilajit topics rest only on preclinical evidence. Look for human trials before believing a benefit claim.

Related reading